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Abstract 
Purpose: The objective of this study was to investigate nationwide survival outcomes in men with 
localized prostate cancer managed on active surveillance. 
Material and methods: 936 men with localized prostate cancer initiated active surveillance in 
Denmark in 2002-2012. Kaplan-Meier estimated curative treatment-free-, hormonal therapy-free-, 
castration-resistant prostate cancer-free- and cause-specific survival were calculated. 
Results: Two hundred and twenty-three men were classified with very low-risk prostate cancer, 436 
men with low-risk prostate cancer, 259 men with intermediate-risk prostate cancer (87% had 
favorable intermediate-risk prostate cancer), and 18 men with high-risk prostate cancer. The median 
follow-up was 7.5 years (IQR 6.1-9.1 years). Kaplan-Meier estimated 10-year curative treatment-free 
survival was 62.8% (95% CI 59.1-66.3%), 10-year hormonal therapy-free survival was 92.2 (95% CI 
89.2-94.4%), 10-year castration-resistant prostate cancer-free survival was 97.2% (95% CI 95.3-
98.4%) and the 10-year cause-specific survival was 99.6% (95% CI 98.6-99.9%). Compared to men 
with low-risk prostate cancer, men with intermediate-risk prostate cancer had a higher curative 
treatment-free survival (69% vs. 56%, p = 0.008), a lower hormonal therapy-free survival (88% vs. 
95%, p = 0.005), and similar castration-resistant prostate cancer-free survival (95% vs. 99%, p = 0.17).  
Conclusion: In this nationwide cohort the 10-year cause-specific survival was similar to prospective 
active surveillance cohorts. Our study supports the use of active surveillance for men with localized 
prostate cancer – including men with favorable intermediate-risk characteristics. 
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INTRODUCTION 
Curative options for localized prostate cancer are available, however, the effect on survival in men 
with more favorable-risk features is very limited1–5. Still, some men with favorable-risk prostate 
cancer dye from the disease1. Active surveillance has been introduced as a tailored management for 
selected men with localized prostate cancer in order to reduce overtreatment by identifying men who 
will likely benefit from definitive therapy, while men with true favorable-risk prostate cancer are 
spared curative interventions and its adverse effects2,3.  
Large prospective active surveillance cohorts with predefined follow-up programs and criteria for 
recommending curative therapy have achieved excellent 10-year cause-specific survival of 98-99%6–9. 
Follow-up in these cohorts include regular prostate-specific antigen (PSA) testing, digital rectal 
examinations and sequential surveillance biopsies. The ProtectT study, the first randomized controlled 
trial comparing curative interventions (i.e. radical prostatectomy and radiotherapy) to an “active 
monitoring” strategy found no survival difference between the treatment strategies10. In that study 
men on active monitoring was managed with regular PSA testing and change to curative treatment 
primarily based on PSA. The 10-year cause-specific survival for men on active monitoring was 98.8%.  
The safety of men with localized prostate cancer managed on active surveillance outside of 
prospective cohorts is unknown. Well conducted observational studies can elucidate on the 
effectiveness of managements in a real world setting and are important additions to clinical trials in 
clinical decision making11,12. The objective of this study was to investigate results for men with 
localized prostate cancer managed on active surveillance in Denmark. We identified men who initiated 
active surveillance in 2002-2012. This enabled us to define a magnetic resonance imaging (MRi) “naïve” 
cohort – i.e. MRi was not part of the diagnostic work-up and for the vast majority a surveillance MRi 
was not available for the initial years of surveillance, the period in which the majority of men on active 
surveillance, who undergo subsequent curative treatment, will change strategy13. 
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MATRIAL AND METHODS 
Patients diagnosed with prostate cancer and initially managed on active surveillance in the period 
between 1 Jan 2002 and 31 December 2012 were identified at ten Danish urological departments 
(Aalborg, Esbjerg, Frederiksberg, Herlev, Næstved, Odense, Rigshospitalet, Roskilde, Skejby, and 
Viborg). Patient chart review was performed at Aalborg, Esbjerg, Frederiksberg, Næstved, Roskilde, 
Skejby, and Viborg for men who had two or more prostate biopsies, while local registration of men on 
active surveillance was performed at Herlev, Odense and Rigshospitalet. The following data was 
retrieved at the time of initiating active surveillance: year, age, clinical tumor category (cT), diagnostic 
Gleason score (recorded according to the five-tier Gleason Grade Group [GGG])14, PSA (ng/mL), 
transrectal ultrasound (TRUS) estimated prostate volume, number of biopsies, number of positive 
core biopsies, and maximum tumor involvement in any one core. Number of surveillance biopsies was 
also registered. Baseline PSA was defined for men diagnosed with biopsy as the last PSA before the 
diagnostic biopsy, while for men diagnosed following transurethral resection of the prostate, the PSA 
nadir after the procedure was used. In men diagnosed following a biopsy PSA density was calculated 
as PSA divided by TRUS estimated prostate volume (ng/mL/cc).  
Prostate cancer was grouped into four risk categories according to a modified NCCN risk 
categorisation2: Very low-risk: cT1 and GGG 1 and PSA <10 and PSA density <0.15 and 1-2 positive 
biopsy cores and ≤50% cancer in any one core; Low-risk: cT1-2a and GGG 1 and PSA <10; 
Intermediate-risk: cT2b-2c and/or GGG 2-3 and/or PSA 10-20; High-risk: PSA >20 (no patients had 
cT3 or GGG 4-5). Intermediate-risk prostate cancer was further sub-divide into favorable (only 1 
intermediate-risk criteria and GGG 1-2 and ≤50% tumor in any one core) or unfavorable (2-3 
intermediate-risk criteria and/or GGG 3 and/or >50% tumor in any one core). 
During March-April 2018 patient chart review was performed to record date and type of all prostate 
cancer treatments, date of fulfilling the EAU’s definition of castration-resistant prostate cancer15, and 
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survival status. Cause of death was defined as prostate cancer or other. Follow-up was calculated from 
start of active surveillance to event of interest or censured at last known date alive. 
The study was approved by the Capital Region of Denmark (file no. 2012-58-0004) and by the Danish 
Patient Safety Authority (file no. 3-3013-1887).  
 
Statistics 
Descriptive statistics was used to describe baseline characteristics. Follow-up was calculated with the 
reverse Kaplan-Meier method. Survival probabilities were assessed with Kaplan-Meier analyses and 
presented with 95% confidence interval (CI). The log-rank test was used to assess differences between 
subgroups. The association between baseline characteristics and subsequent treatments were 
assessed with Cox proportional hazard regression analyses including the following categorical 
variables: year of commencing active surveillance, age, cT, PSA, PSA density, GGG, number of positive 
biopsy cores, and maximum percent tumor in any one core. Missing values were included in as an 
individual group. Results are presented as hazard ratios (HR) with 95% CI. Statistical analysis was 
performed using R (R Foundation for Statistical Computing, Vienna, Austria). All tests were two-sided 
and the significance level was set to p < 0.05.  
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RESULTS 
In total, 936 men diagnosed with prostate cancer and initially followed on active surveillance were 
identified, Table 1. The median follow-up was 7.5 years (Interquartile range [IQR] 6.1-9.1 years) and 
840 men (90%) underwent at least one surveillance biopsy, the median number of surveillance 
biopsies were 2 (IQR 1-2). The majority was classified with very low-risk prostate cancer (24%) or 
low-risk prostate cancer (47%), while 28% had intermediate-risk prostate cancer (of which 33 men 
had unfavorable intermediate-risk prostate cancer), and 2% high-risk prostate cancer (all because of a 
PSA above 20).  
During follow-up 320 men underwent curative treatment. Two hundred and fifty men underwent 
radical prostatectomy, 53 men underwent external beam radiotherapy, 15 men underwent 
brachytherapy and 2 men underwent a radical cystoprostatectomy because of a subsequent bladder 
cancer. The 5-year curative treatment-free survival was 69.1% (95% CI 66.0-71.9%) and the 10-year 
curative treatment-free survival was 62.8% (95% CI 59.1-66.3%), Figure 1A. Men diagnosed in 2010-
2012 and men aged 70 years or older at diagnosis were less likely to undergo curative treatment, 
whereas a PSA density higher than 0.1 was associated with an increased risk of undergoing curative 
treatment, Table 2.  
In sub-group analyses, with men with low-risk prostate cancer as reference, the curative treatment-
free survival was higher in men with very low-risk (p = 0.005) and intermediate-risk prostate cancer 
(p = 0.008), but similar to men with high-risk prostate cancer (p = 0.59), Table 3.  
Ninety-one men died during follow-up – three from prostate cancer. Corresponding to a 10-year 
overall survival of 87.2% (95% CI 84.0-89.9) and a 10-year cause-specific survival of 99.6% (95% CI 
98.6-99.9), Figure 1B. There was no difference between risk groups, Table 3. Two of the three men 
who died of prostate cancer were classified with low-risk prostate cancer, while the third man had 
intermediate-risk prostate cancer. Two of the three men underwent radical prostatectomy within one 
year of initiating surveillance and both experience early biochemical recurrence and commenced 
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hormonal therapy. The third man with low-risk prostate cancer was diagnosed with distant 
metastases following 3 years of surveillance and commenced hormonal therapy. Imaging in this man 
was performed during work-up following a surveillance biopsy, which revealed an upgrade to GGG 4.  
Fifty men (5%) commenced hormonal therapy (i.e. antiandrogen monotherapy [n = 27] or castration 
therapy [n =23]) during follow-up corresponding to a 10-year hormonal therapy-free survival of 
92.2% (95% CI 89.2-94.4%), Table 3. No difference was observed between men who had undergone 
curative treatment and men who had not, Figure 2A. Men aged 70 years or older, men with a PSA 
higher than 5, and men with a missing PSA density (including the 64 men diagnosed following TUR-P) 
had a higher risk of commencing hormonal therapy, Table 2. Compared to men with low-risk prostate 
cancer, men with intermediate-risk prostate cancer (p = 0.005) and men with high-risk prostate 
cancer (p <0.001) had a lower hormonal therapy-free survival, Table 3. 
Finally, the 10-year castration-resistant prostate cancer-free survival was 97.2% (95% CI 95.3-98.4%), 
Table 3. Again no difference between men who had undergone curative treatment and men who had 
not, Figure 2B. Men with high-risk prostate cancer had a lower castration-resistant prostate cancer-
free survival compared to men with low-risk prostate cancer, p <0.001; whereas there was no 
difference between men with low-risk and intermediate risk prostate cancer, p = 0.17, Table 3. 
Compared to men with favorable intermediate-risk prostate cancer men with unfavorable 
intermediate-risk prostate cancer were more likely to receive hormonal therapy and had a higher risk 
of developing castration-resistant prostate cancer, Supplemental Table.
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DISCUSSION 
In this nationwide, observational study on men with localized prostate cancer managed on active 
surveillance in Denmark we found 10-year cause-specific survival similar to prospective active 
surveillance cohorts.  
The main limitation of the retrospective design is potential incomplete capture as there was no 
national database in the period studied with data on which men were managed on active surveillance. 
Moreover, 11 Danish urological departments were primary referral centers in the period studied; 
however, one department chose not to participate. Although this department refers men diagnosed 
with prostate cancer who are candidates for curative treatment to a tertiary referral center, it is 
possible that men diagnosed at this department were not included in the study. Another limitation of 
the design is that there was no uniform surveillance strategy at the different departments. However, 
all centers assessed men with a combination of surveillance biopsies, regular PSA measurement and 
digital rectal examinations. On the other hand thorough patient chart review was performed in all 
identified men with almost complete baseline data and complete follow-up including all cancer 
therapies utilized and survival status.  
The short-term, 5-year curative treatment-free survival of 69.1% is higher than what is observed in 
the prospective cohorts (50-64%)6–9, which could indicate that the men in the current study were 
managed with a less intensive surveillance i.e. fewer surveillance biopsies with a subsequent lower 
risk of biopsy reclassification. Another possibility is that more frequent change from active 
surveillance to watchful waiting – i.e. a strategy where curative treatment is no longer considered an 
option and men are only followed with PSA and digital rectal examination in order to initiate 
subsequent hormonal therapy when required. This in particular seems the case for men aged 70 year 
or older, who were less likely to undergo curative treatment but more likely to commence hormonal 
therapy. Surprisingly and somewhat counterintuitive, we observed a higher curative treatment-free 
survival in men with intermediate-risk prostate cancer compared to men with low-risk prostate 
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cancer. It is likely that men with intermediate-risk prostate cancer had reluctance towards curative 
treatment at diagnosis and that progression on surveillance biopsies leading to recommending 
curative treatment is less likely for men with GGG 2 compared to men with GGG 1.  
The current study constitutes an active surveillance cohort of men where a relatively large proportion 
(30%) had intermediate-risk or high-risk prostate cancer compared to published prospective cohorts 
(0-25%)6–9. Still, with a 10-year cause-specific survival of 99.6% we confirm that active surveillance in 
a real world setting can produce survival results similar to prospective active surveillance cohorts (98-
99%)6,7 and the active monitoring arm of the ProtecT study (98.8%)10. However, there are still 
concerns about this strategy’s long-term safety. The prospective Swedish, Örebro cohort study and a 
Danish register-based study have demonstrated that the cause-specific mortality is not insignificant in 
men managed on watchful waiting and surviving 10 years or more16,17. Importantly in these studies 
curative treatments were not available and the Sunnybrook active surveillance cohort demonstrated a 
15-year cause-specific mortality half of the observed in the comparable subgroup in the Örebro cohort 
(5.7% vs. 11%)6. Moreover, a previous report from the Sunnybrook cohort have questioned the safety 
of active surveillance in men with intermediate-risk prostate cancer18. However, that study only 
included men with intermediate-risk prostate cancer diagnosed before 2000. The current study almost 
exclusively included men with favorable intermediate-risk prostate cancer and the vast majority was 
diagnosed after 2005. It is therefore likely that the changes made to the Gleason reporting in 200519, 
with the subsequent improved prognosis in men with GGG 220,21, is one of the reasons for the better 
outcomes among men with intermediate-risk prostate cancer in the current study. 
The practice in Denmark is to initiate castration therapy if imaging detects metastatic disease; 
whereas, antiandrogen monotherapy is initiated in men on surveillance who no longer are candidates 
to curative treatment without presence of metastases, if extraprostatic extension is suspected on 
digital rectal examination, if the PSA level rises rapidly and/or reaches a level above 50 or following 
curative treatment if distant failure is suspected. Thus, we were not able to assess metastases-free 
survival. We observed no difference in these surrogate endpoints, hormonal therapy-free and 
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castration-resistant prostate cancer-free survival, between men who had undergone curative 
treatment and men who had not. This indicates that only few men who could have benefitted from 
curative treatment do not undergo such interventions. Although these results are promising men on 
active monitoring in the ProtecT study had a higher risk of clinical progression including progression 
to metastatic disease compared to men who underwent curative interventions10. Thus, more studies 
comparing active surveillance to curative treatment modalities are still warranted.  
Even though active surveillance is an accepted treatment strategy and recommended in guidelines to 
men with very low- or low-risk prostate cancer2,3 the strategy is evolving. Roughly one third of men 
with low-risk prostate cancer who undergo immediate radical prostatectomy harbor GGG 2 or higher 
and more than 10% present with extra prostatic extension in the prostatectomy specimen22. On the 
other hand up to 50% of men who progressed on active surveillance and undergo radical 
prostatectomy had true low-risk disease at surgery – i.e. pT2 and GGG 122. Efforts are made to increase 
the precision in which curative treatments are recommended23–25. Currently multiparametric MRi is 
the only marker that has been recommend in the EAU guidelines and introduced in the management of 
men on active surveillance on a large scale3,6,24. This modality seems able to detect potential lethal 
tumors missed by TRUS guided biopsy26; however, this could also lead to new overtreatment issues as 
we still do not fully understand how to clinical interpret the pathology of an MRi targeted biopsy. 
Moreover, it seems unlikely that an active surveillance program including MRi can achieve better 
outcomes in terms of cancer-specific survival. On the other hand MRi may in the future enable us to 
broaden the selection criteria for active surveillance, reduce the number of surveillance biopsies, and 
decrease the number of men who need to undergo curative treatments. 
  
CONCLUSION 
In this nationwide, observational study on men with localized prostate cancer managed on active 
surveillance in Denmark, we found cause-specific survival similar to prospective active surveillance 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
cohorts in the intermediate timeframe. Men with intermediate-risk prostate cancer were less likely to 
undergo curative treatment but had similar castration-resistant treatment-free survival compared to 
men with low-risk prostate cancer. Our study supports active surveillance as a treatment strategy for 
men with localized prostate cancer – including men with intermediate-risk characteristics. 
 
 
Figure legends 
Figure 1   Curative treatment-free survival (A) and overall- and cause-specific survival (B) estimates 
with 95% confidence intervals of 936 men with localized prostate cancer managed on active 
surveillance in Denmark. 
 
Figure 2   Hormonal therapy-free survival (A) and castration-resistant prostate cancer-free survival 
(B) estimates with 95% confidence intervals of 936 men with localized prostate cancer managed on 
active surveillance in Denmark stratified according to curative treatment interventions. 
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Table 1   Diagnostic characteristics of 936 men on active surveillance in Denmark in 2002-2012 
 
N % 
Year of commencing active surveillance 
  
 
2002-2005 60 (6) 
 
2006-2009 359 (38) 
 
2010-2012 517 (55) 
Age, years 
  
 
Median (IQR) 66 (63-68) 
 
<60 103 (11) 
 
60-64 260 (28) 
 
65-69 419 (45) 
 
≥70 154 (16) 
Clinical tumour category 
  
 
cT1a/b 64 (7) 
 
cT1c 734 (78) 
 
cT2a 106 (11) 
 
cT2b 20 (2) 
 
cT2c 12 (1) 
Gleason Grade Groups 
  
 
1 841 (90) 
 
2 85 (9) 
 
3 10 (1) 
Prostate-specific antigen, ng/mL 
  
 
Median (IQR) 6.7 (5.2-9.2) 
 
<5 193 (21) 
 
5-<10 567 (61) 
 
10-20 158 (17) 
 
>20 18 (2) 
PSA density, ng/mL/cc 
  
 
Median (IQR) 0.15 (0.10-0.21) 
 
<0.10 166 (18) 
 
0.10-<0.20 413 (44) 
 
0.20-0.50 238 (25) 
 
>0.50 25 (3) 
 
Missing 94 (10) 
Number of biopsy cores   
 Median (IQR) 10 (10-12) 
Number of positive biopsy cores 
  
 
1-2 735 (79) 
 
3-4 103 (11) 
 
5-6 13 (1) 
 
7-8 2 (0.2) 
 
9-10 2 (0.2) 
 
Missing 81 (9) 
Maximum percent tumour in any one core  
 
 
Median (IQR) 0.10 (0.05-0.20) 
 
<0.10 377 (40) 
 
0.10-<0.25 348 (37) 
 
0.25-0.50 131 (14) 
 
>0.50 18 (2) 
 
Missing 62 (7) 
NCCN risk category* 
  
 
Very Low-risk 223 (24) 
 
Low-risk 436 (47) 
 
Intermediate-risk 259 (28) 
 
High-risk 18 (2) 
* Risk category definition:  
Very low-risk: cT1 and GGG 1 and PSA less than 10 ng/mL and PSA density less than 0.15 ng/mL/cc and 1-2 
positive biopsy cores and maximum 50% cancer in any one core;  
Low-risk: cT1-2a and GGG 1 and PSA less than 10 ng/mL;  
Intermediate-risk: cT2b-c and/or GGG 2-3 and/or PSA 10-20 ng/mL;  
High-risk: PSA higher than 20 ng/mL 
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Table 2   Association between baseline characteristics and undergoing curative treatment or commencing 
hormonal therapy. Multivariable Cox regression analysis 
 Curative treatment Hormonal therapy 
 
HR 95% CI HR 95% CI 
Year of commencing active surveillance 
  
  
 
2002-2005 1 ref 1 ref 
 
2006-2009 0.75 0.50-1.15 0.64 0.26-1.59 
 
2010-2012 0.65 0.42-1.00 0.51 0.20-1.33 
Age, years 
  
  
 
<60 1 ref 1 ref 
 
60-64 1.03 0.72-1.49 0.72 0.21-2.53 
 
65-69 0.85 0.59-1.22 1.20 0.39-3.67 
 
≥70 0.42 0.26-0.69 3.09 1.01-9.46 
Clinical tumour category 
  
  
 
1 1 ref 1 ref 
 
2 1.21 0.89-1.65 0.71 0.31-1.67 
Prostate-specific antigen, ng/mL 
  
  
 
<5 1 ref 1 ref 
 
5-<10 1.01 0.72-1.42 3.64 1.10-12.01 
 
10-20 0.90 0.57-1.42 4.76 1.30-17.44 
 
>20 1.13 0.47-2.71 13.08 2.38-71.87 
PSA density, ng/mL/cc 
  
  
 
<0.10 1 ref 1 ref 
 
0.10-<0.20 1.47 1.03-2.10 0.73 0.27-1.93 
 
0.20-0.50 1.65 1.11-2.46 1.11 0.41-3.03 
 
>0.50 2.71 1.27-5.74 2.53 0.54-11.89 
 
Missing 1.68 0.82-3.46 5.79 1.67-20.07 
Gleason Grade Group 
  
  
 
1 1 ref 1 ref 
 
2 0.80 0.51-1.26 1.93 0.80-4.66 
 
3 0.75 0.23-2.42 3.80 0.82-17.63 
Number of positive biopsy cores 
  
  
 
1-2 1 ref 1 ref 
 
3-4 1.78 1.28-2.48 0.92 0.34-2.48 
 
5-10 1.44 0.67-3.11 1.34 0.18-10.24 
 
Missing 0.67 0.31-1.47 0.42 0.10-1.76 
Maximum percent tumour in any one core 
  
  
 
<0.10 1 ref 1 ref 
 
0.10-<0.25 1.12 0.86-1.46 1.27 0.63-2.56 
 
0.25-0.50 1.10 0.76-1.60 1.24 0.51-3.02 
 
>0.50 1.09 0.49-2.49 2.68 0.55-13.11 
 
Missing 1.45 0.95-2.23 0.60 0.13-2.76 
Abbreviations  HR hazard ratio; CI confidence interval   
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Table 3   Survival probabilities estimated with Kaplan-Meier analyses for all men managed on active surveillance and stratified on risk category* 
All Very low-risk Low-risk Intermediate-risk High-risk 
n = 936 n = 223 n = 436 n = 259 n = 18 
Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI Estimate 95% CI 
Curative treatment 
3-year 75.3 72.4-78.0 79.8 73.9-84.5 71.6 67.1-75.6 78.2 72.7-82.8 66.7 40.4-83.4 
5-year 69.1 66.0-71.9 73.4 67.0-78.7 64.5 59.8-68.8 73.5 67.6-78.5 61.1 35.3-79.2 
10-year 62.8 59.1-66.3 70.8 64.0-76.5 55.7 49.9-61.0 69.0 61.8-75.0 - - 
Hormonal therapy 
5-year 97.1 95.8-98.0 98.2 95.3-99.3 97.9 96.0-98.9 95.7 92.4-97.6 82.4 54.7-93.9 
10-year 92.2 89.2-94.4 95.1 89.6-97.7 94.6 90.0-97.1 87.7 79.1-92.6 57.0 26.5-78.8 
Castration-resistant prostate cancer 
5-year 99.6 98.8-99.8 - - 99.3 97.8-99.8 99.6 97.2-99.9 - - 
10-year 97.2 95.3-98.4 98.5 93.8-99.6 98.7 96.9-99.5 94.7 87.7-97.7 80.0 40.9-94.6 
Overall survival 
5-year 95.4 93.9-96.6 95.5 91.8-97.6 95.2 92.7-96.8 95.8 92.5-97.6 94.4 66.6-97.6 
10-year 87.2 84.0-89.9 88.6 81.5-93.2 87.9 83.5-91.2 83.9 75.1-89.7 - - 
Cause-specific survival 
5-year - - - - - - - - - - 
10-year 99.6 98.6-99.9 - - 99.3 97.3-99.8 99.5 96.6-99.9 - - 
Abbreviations   CI confidence interval 
*Risk category definition:  
Very low-risk: cT1 and GGG 1 and PSA less than 10 ng/mL and PSA density less than 0.15 ng/mL/cc and 1-2 positive biopsy cores and maximum 50% cancer in any one core;  
Low-risk: cT1-2a and GGG 1 and PSA less than 10 ng/mL;  
Intermediate-risk: cT2b-c and/or GGG 2-3 and/or PSA 10-20 ng/mL;  
High-risk: PSA higher than 20 ng/mL 
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Abbreviations 
 
CI: confidence interval 
cT: clinical tumour category 
GGG: Gleason Grade Group 
HR: hazard ratios 
MRi: magnetic resonance imaging 
TRUS: transrectal ultrasound 
PSA: prostate-specific antigen 
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Supplemental table   Survival probabilities estimated with Kaplan-Meier analyses for men with intermediate-risk prostate cancer managed on active 
surveillance and stratified on favourable and unfavourable intermediate-risk* 
Intermediate-risk Favourable intermediate-risk Unfavourable intermediate-risk  
n = 259 n = 226 n = 33  
Estimate 95% CI Estimate 95% CI Estimate 95% CI p 
Curative treatment 0.49 
3-year 78.2 72.7-82.8 79.0 73.1-83.8 72.7 54.1-84.8  
5-year 73.5 67.6-78.5 74.5 68.3-79.7 66.4 47.6-79.8  
10-year 69.0 61.8-75.0 69.1 61.1-75.8 66.4 47.6-79.8  
Hormonal therapy 0.03 
5-year 95.7 92.4-97.6 97.3 94.1-98.8 84.8 67.4-93.4  
10-year 87.7 79.1-92.6 88.3 77.7-94.0 81.5 63.2-91.2  
Castration-resistant prostate cancer 0.02 
5-year 99.6 97.2-99.9 99.6 96.9-99.9 - -  
10-year 94.7 87.7-97.7 96.1 87.6-98.8 86.3 61.8-95.6  
Overall survival 0.33 
5-year 95.8 92.5-97.6 95.6 91.9-97.6 97.0 80.4-99.6  
10-year 83.9 75.1-89.7 83.9 74.9-89.8 83.1 37.5-96.6  
Cause-specific survival 0.69 
5-year - - - - - -  
10-year 99.5 96.6-99.9 99.4 96.1-99.9 - -  
Abbreviations   CI confidence interval 
*Risk category definition:  
Intermediate-risk: cT2b-c and/or GGG 2-3 and/or PSA 10-20 ng/mL 
Favourable: Maximum of one intermediate-risk criteria and GGG 1-2 and maximum 50% cancer in any one core 
Unfavourable: More than one intermediate-risk criteria and/or GGG 3 and/or more than 50% cancer in any one core 
 
